Goodbye, Kidney Disease.
Hello, Kidney Health.
Traditional clinical kidney measurements are flawed.
Physicians typically look at estimated GFR and urinary albumin creatinine ratio levels, but they are inadequate in identifying those select patients who are more likely to experience progressive decline in kidney function.
That changes now… with kidney bioprognosis™.
Renalytix is the global founder and leader in the new field of bioprognosis for kidney health. We’ve engineered a new solution that successfully enables early-stage, progression risk assessment, when it counts the most.
Our proprietary platform, KidneyIntelXTM, is at the core of our solution offering.
With KidneyIntelX, we take diverse and proprietary data inputs and maximize their value through our AI-enabled algorithm. This allows us to generate an accurate kidney disease risk score – identifying those patients with kidneys at the most risk – to guide ongoing, clinical decisions.
Our out-of-the-gate focus: Diabetic Kidney Disease.
Diabetes is the leading cause of chronic kidney disease, representing nearly 40% of its cases. That’s why our first KidneyIntelX indication is focused on diabetic kidney disease.
(Source: cjasn.asnjournals.org › content › 12/12/2032)
And our test platform eliminates the grey area common in diabetic kidney disease.
Currently, doctors are unable to determine which of the 1 in 5 patients with type 2 diabetes and chronic kidney disease are at the highest risk for rapid progressive decline in kidney function – vs those who are at lower risk. KidneyIntelX is the only test that identifies which patients are at higher-to-lower risk to help guide an actionable, targeted plan for what’s next.
KidneyIntelX. Designed to be scalable. Additional discoveries and developments in novel biomarkers, expanded clinical indications and integrated digital technologies.
Our KidneyIntelX platform is designed to scale across kidney disease conditions beyond diabetic kidney disease. We are evaluating a range of new indications in chronic kidney disease, cardio-renal disease, chronic kidney disease in diverse populations and COVID-related kidney disease. We’re also continuing our next generation work on our current diabetic kidney disease indication while we explore ways to expand access to patients around the world.
Critical to our platform is also the ability to stay at the forefront of cloud based digital health technology, data integration and data analytics, which we’re accomplishing through our newly-established Digital Health Team, various strategic partnerships and our participation in how category regulations should evolve. All of these will enable the most effective data-driven decision making and care delivery across the healthcare system and for each patient.
Get access to the blog, webinars and podcasts with the ideas, perspectives and innovations that matter most in kidney health.